The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

View Congress Resources by Therapeutic Area
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Showing 6 of 46 results
Sort by date: Descending
Encores: Not included
Research Society on Alcohol
June 21st – 25th 2025
Alcohol Use Disorder
POSTER
Use of Primary and Specialist Care Among Patients with Chronic Medical Conditions With or Without Comorbid Alcohol Use Disorder
AUTHOR(S)

Regina Grebla;1 Xin Zhao;2 Lucas Watterson;1 Allison Keshishian2

View poster
Listen to Audio Abstract
0:00 0:00
Alcohol Use Disorder
SLEEP (Annual Meeting of the Associated Professional Sleep Societies)
June 7th – 11th 2025
Sleep-wake disorders
POSTER
The Clinical and Humanistic Burden of Narcolepsy: Matched Analysis of US National Health and Wellness Survey Data
AUTHOR(S)

Kiran P. Maski,1 Michael J. Doane,2 M. Janelle Cambron-Mellott,3 Shakiba Eslamimehr,3 Adam Jauregui,3 Wilbur P. Williams, III2

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Sleep-wake disorders
POSTER
Vibrance-3: Study Design and Methods for a Phase 2, Randomized, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of ALKS 2680 in Patients With Idiopathic Hypersomnia
AUTHOR(S)

David Plante,1 Ron Grunstein,2 Giuseppe Plazzi,3 Kiran Maski,4 Jandira Ramos,5 Yangchun Du,5 Alexandra Lovett,5 Marcus Yountz,5 Bhaskar Rege5

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Sleep-wake disorders
POSTER
Evaluation of Cardiac Safety Profile of ALKS 2680 in Healthy Subjects: Concentration-QTc Relationship of ALKS 2680
AUTHOR(S)

Jahnavi Kharidia,1 Borje Darpo,2 Sergey Yagoda,1 Alexandra Lovett,1 Hongqi Xue,2 Hailu Chen,1 Bhaskar Rege,1 Ishani Landry1

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Sleep-wake disorders
POSTER
Diagnosis Journey, Symptoms, and Burden of Idiopathic Hypersomnia: Patient Perspectives from Qualitative Interviews
AUTHOR(S)

Michael J. Doane,1 Meaghan O’Connor,2 Miranda Lauher-Charest,2 Laura Tesler Waldman,2 and Wilbur P. Williams, III1

View poster
Listen to Audio Abstract
0:00 0:00
Sleep-wake disorders
Sleep-wake disorders
POSTER
Effects of the Orexin 2 Receptor Agonist ALKS 2680 on qEEG in Patients With Narcolepsy and Idiopathic Hypersomnia
AUTHOR(S)

Meera Modi,1 Brendon Yee,2 Julia Chapman,2 Angela D’Rozario,2 Roman Rosipal,3 Leonardo Jose Trejo,3 G.S.F. Ruigt,3 Ron Grunstein,2 Bhaskar Rege,1 Daniel G. Smith1

View poster
Sleep-wake disorders